Fig 1: Effects of coixol on protein expression of phosphorylated NF-κB p65, phosphorylated p38, iNOS, RAGE, and Nrf2. NGF-differentiated PC12 cells were pretreated with coixol at 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, or 2 μM for 48 h, followed by Abeta25-35 exposure for 24 h. Normal groups had no coixol or Abeta25-35. Abeta groups had no coixol, but with Abeta25-35. Data are expressed as mean ± SD (n = 8). a: P < 0.05 compared the normal; b: P < 0.05 compared Abeta; c: P < 0.05 compared coixol 0.125 + Abeta; d: P < 0.05 compared coixol 0.25 + Abeta; e: P < 0.05 compared coixol 0.5 + Abeta; and f: P < 0.05 compared coixol 1 + Abeta. iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor kappa B; NGF, nerve growth factor; RAGE, receptor of advanced glycation end product; SD, standard deviation.
Fig 2: (A) Quantitation SP-D mRNA expression in lung tissues obtained from all mouse groups. The data are presented as fold change relative to the expression in naïve mice treated with the DMSO (0.01%), with GAPDH as the normalization housekeeping gene. Alveolar cells of (B) type 1 and (C) type 2 were assessed for percent apoptosis (annexin-V+/PI−). A multiplexed sandwich enzyme-linked immunosorbent assay-based technology was used to simultaneously determine the concentration of (D) sRAGE and (E) pro-inflammatory cytokines of IL-1β, TNFα, IL-6, and IL-4. (F) RT-PCR of ENaC, CFTR, and AQP5 alveolar fluid transport and data represented as fold change compared to naïve mice. Data are represented as averages ± SD (n = 11 per group). Significance was determined using Newman–Keuls two-way analysis of variance (ANOVA), *p < 0.01, **p < 0.001, ***p < 0.0001, ****p < 0.00001.
Supplier Page from Abcam for Mouse RAGE ELISA Kit